CO2024005662A2 - Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1 - Google Patents

Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1

Info

Publication number
CO2024005662A2
CO2024005662A2 CONC2024/0005662A CO2024005662A CO2024005662A2 CO 2024005662 A2 CO2024005662 A2 CO 2024005662A2 CO 2024005662 A CO2024005662 A CO 2024005662A CO 2024005662 A2 CO2024005662 A2 CO 2024005662A2
Authority
CO
Colombia
Prior art keywords
methods
administering
effect
npr1
hemodynamic change
Prior art date
Application number
CONC2024/0005662A
Other languages
English (en)
Spanish (es)
Inventor
Michael Dunn
Aaron Kithcart
Benjamin Adam Olenchock
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2024005662A2 publication Critical patent/CO2024005662A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2024/0005662A 2021-10-11 2024-04-30 Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1 CO2024005662A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163254447P 2021-10-11 2021-10-11
PCT/US2022/077908 WO2023064769A1 (en) 2021-10-11 2022-10-11 Methods of effecting a hemodynamic change by administering an anti-npr1 antibody

Publications (1)

Publication Number Publication Date
CO2024005662A2 true CO2024005662A2 (es) 2024-05-10

Family

ID=84045029

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0005662A CO2024005662A2 (es) 2021-10-11 2024-04-30 Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1

Country Status (12)

Country Link
US (2) US20240327539A1 (enExample)
EP (1) EP4415820A1 (enExample)
JP (1) JP2024537284A (enExample)
KR (1) KR20240099275A (enExample)
CN (1) CN118159290A (enExample)
AU (1) AU2022363841A1 (enExample)
CA (1) CA3234238A1 (enExample)
CL (1) CL2024001071A1 (enExample)
CO (1) CO2024005662A2 (enExample)
IL (1) IL311917A (enExample)
MX (1) MX2024004302A (enExample)
WO (1) WO2023064769A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024542823A (ja) 2021-12-06 2024-11-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンタゴニスト抗ｎｐｒ１抗体およびその使用方法
AU2024287056A1 (en) * 2023-06-08 2025-12-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-npr1 antibody and pharmaceutical use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
WO2010065293A1 (en) 2008-12-03 2010-06-10 Boehringer Ingelheim Pharmaceuticals Inc. Antibodies for guanylyl cyclase receptors
KR20210082207A (ko) 2018-10-23 2021-07-02 리제너론 파아마슈티컬스, 인크. 항-npr1 항체 및 이의 용도
US11066469B2 (en) * 2019-06-12 2021-07-20 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
US12325752B2 (en) * 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists

Also Published As

Publication number Publication date
JP2024537284A (ja) 2024-10-10
AU2022363841A1 (en) 2024-03-28
KR20240099275A (ko) 2024-06-28
EP4415820A1 (en) 2024-08-21
CA3234238A1 (en) 2023-04-20
US20240327539A1 (en) 2024-10-03
US20250034279A1 (en) 2025-01-30
CL2024001071A1 (es) 2024-12-06
IL311917A (en) 2024-06-01
CN118159290A (zh) 2024-06-07
WO2023064769A1 (en) 2023-04-20
MX2024004302A (es) 2024-06-19

Similar Documents

Publication Publication Date Title
CO2024005662A2 (es) Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
NI202100009A (es) Métodos para reducir la necesidad de revascu
MX2022004678A (es) Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
BR112022001308A2 (pt) Inibidores tricíclicos de kars dependentes de akr1c3
AR096762A1 (es) Oligomerización de corrientes de c₄ con muy bajo contenido de 1-buteno
MX2021015153A (es) Composicion farmaceutica parenteral de agonista dual de glp1/2.
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
CO2021007613A2 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
CL2023003124A1 (es) Anticuerpos anti-tslp modificados
CU24743B1 (es) Composiciones inmunogénicas contra el coronavirus
CO2023013543A2 (es) Anticuerpos anti-cd20 y estructuras car-t
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
CL2024000829A1 (es) Formas sólidas de un inhibidor ge glyt1
CL2021000849A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999)
MX2021014465A (es) Construcciones de arni para inhibir la expresion de scap y metodos de uso de las mismas.
AR100132A1 (es) Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino
CL2025000292A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos
PE20221009A1 (es) Sintesis de un inhibidor de calicreina plasmatica a escala de proceso
MX2022006670A (es) Region fc de anticuerpo teniendo mayor afinidad de union al fcyriib.
MX2024011128A (es) Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico.
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
MX2025001942A (es) Métodos de administración de componentes a microorganosferas